Truking(SZ:300358)2025-06-13 09:46Group 1: International Market Expansion - The company has established localized sales and service networks in over 10 key countries and regions, enhancing its international business localization strategy [2] - In 2024, the company achieved new export orders exceeding 1.2 billion, with products entering high-end markets in Europe [2] - The company has divided its global market into five regional departments to strengthen international sales and service responsiveness [2] Group 2: Order Delivery and Revenue Recognition - The manufacturing cycle for main products typically ranges from 3 to 9 months, with revenue recognition based on customer acceptance [3] - For domestic orders, revenue is recognized upon obtaining the customer's signed acceptance, while for international orders, it is recognized upon receipt of customs and shipping documents [3] Group 3: Impact of Tariffs and Supply Chain - The impact of U.S. tariffs on the company's sales is minimal, as exports to the U.S. constitute a very small portion of overall revenue [3] - The company has invested in self-research for core components, reducing reliance on U.S. imports, and can substitute with domestic or other imported brands [3] Group 4: Development in Peptide Field - In August 2023, the company established a joint venture in peptide synthesis equipment, with total assets of approximately 15.6 million and a net profit of about 5.3 million by the end of 2024 [3] Group 5: AI Integration in Business - The company is leading the pharmaceutical equipment industry in developing smart pharmaceutical factories, focusing on both hardware and software investments [3] - The strategy aims to enhance production capabilities through AI technology, improving user value [3]